跳至主要内容
临床试验/NCT00367731
NCT00367731已完成不适用

Neurological Outcomes With in THAI National HAART Program.

Rajavithi Hospital3 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2005年1月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
500
试验地点
3

研究概览

简要总结

After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4<200cell/cu.mm. or in symptomatic HIV with CD4<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded.

Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.

研究设计

研究类型
Observational
观察模型
Defined Population
时间视角
Other

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV/AIDS patients.
  • Age >15 years.
  • informed consent

排除标准

  • Not informed consent

研究者

申办方类型
Other Gov

研究点 (3)

Loading locations...

相似试验

NOW Thai HAART Study | 临床试验